investors.diffusionpharma.com investors.diffusionpharma.com

investors.diffusionpharma.com

Diffusion Pharmaceuticals Inc. | Investor Overview

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Diffusion Pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. December 12, 2016. November 14, 2016. November 08, 2016. Tuesday, June 21, 2016. THE SITE ...

http://investors.diffusionpharma.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTORS.DIFFUSIONPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

September

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Thursday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.5 out of 5 with 14 reviews
5 star
3
4 star
5
3 star
4
2 star
0
1 star
2

Hey there! Start your review of investors.diffusionpharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

1.6 seconds

CONTACTS AT INVESTORS.DIFFUSIONPHARMA.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Diffusion Pharmaceuticals Inc. | Investor Overview | investors.diffusionpharma.com Reviews
<META>
DESCRIPTION
Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Diffusion Pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. December 12, 2016. November 14, 2016. November 08, 2016. Tuesday, June 21, 2016. THE SITE ...
<META>
KEYWORDS
1 company overview
2 management team
3 board of directors
4 intellectual property
5 careers
6 indications
7 treatment resistant cancerous tumors
8 glioblastoma multiforme
9 pancreatic cancer
10 brain metastases
CONTENT
Page content here
KEYWORDS ON
PAGE
company overview,management team,board of directors,intellectual property,careers,indications,treatment resistant cancerous tumors,glioblastoma multiforme,pancreatic cancer,brain metastases,technology,technology overview,scientific papers,product pipeline
SERVER
Microsoft-IIS/8.5
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Diffusion Pharmaceuticals Inc. | Investor Overview | investors.diffusionpharma.com Reviews

https://investors.diffusionpharma.com

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Diffusion Pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. December 12, 2016. November 14, 2016. November 08, 2016. Tuesday, June 21, 2016. THE SITE ...

INTERNAL PAGES

investors.diffusionpharma.com investors.diffusionpharma.com
1

Diffusion Pharmaceuticals Inc. | News Releases

http://investors.diffusionpharma.com/News

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Subscribe for Email Alerts. Subscribe to RSS feed. Diffusion Pharmaceuticals’ TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published in February 2017 Edition of Journal of Neurosurgery. Download - XLS - 3.5MB. Download - XLS - 3.5MB. Download - XLS - 3.5MB. CHARLOTTESVILLE, Va., Nov. 08, 20...CHARL...

2

Diffusion Pharmaceuticals Inc. | Presentations

http://investors.diffusionpharma.com/Presentations

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Notify me of new presentations posted to this site. Diffusion Pharmaceutical Presentation, November 2016. JMP 2016 Life Sciences Conference Presentation. Diffusion Pharmaceuticals at JMP Securities 2016 Life Sciences Conference. Diffusion Pharmaceuticals at BIO CEO and Investor 2016 Presentation. These Terms of Us...

3

Diffusion Pharmaceuticals Inc. | Investor Overview

http://investors.diffusionpharma.com/CorporateProfile

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Diffusion Pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. February 08, 2017. December 12, 2016. November 14, 2016. Tuesday, June 21, 2016. THE SITE ...

4

Diffusion Pharmaceuticals Inc. | Stock Information

http://investors.diffusionpharma.com/Stock

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Select link to view descriptions of our traded funding issues. Historic Price Look Up. Enter a date below to request the closing price for that specific day:. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the entire agreement between the parties with respect to its subject mat...

5

Diffusion Pharmaceuticals Inc. | SEC Filings

http://investors.diffusionpharma.com/Docs

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Please click to return to the document group list. View Insider related Regulatory Filings: Forms 3, 4 and 5. View Document Grouping descriptions. Diffusion Pharmaceuticals, Inc. 8-K filed by Diffusion Pharmaceuticals Inc. (DFFN) covering Regulation FD Disclosure and Financial Statements and Exhibits. 8-K filed by...

UPGRADE TO PREMIUM TO VIEW 4 MORE

TOTAL PAGES IN THIS WEBSITE

9

OTHER SITES

investors.dentsplysirona.com investors.dentsplysirona.com

Dentsply Sirona - Investors - Investors

Press Releases and News. Welcome to Dentsply Sirona's Investor Relations web site. Whether you're a Dentsply Sirona investor or potential investor - or simply want to learn more about our Company - we hope you'll find the information here useful and interesting. Press Releases and News. Financial Information and Quarterly Results. Data as of 01/11/17 4:15 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. VP, Investor Relations. VP, Investor Relations and Corporate Communications.

investors.dft.com investors.dft.com

Investor Relations Services for DFT - DuPont Fabros Technology

Skip to main content. Call Us 202.728.0044. A successful company, like a new data center, starts with an effective blueprint. We designed ours to PERPETUATE profitable growth. News, Events,. Q4 2016 DuPont Fabros Technology, Inc. Earnings Conference Call. 160;at 10:00 am ET. Q4 2016 DuPont Fabros Technology, Inc. Earnings Conference Call. Thursday, February 23, 2017 . 10:00 am ET  . Click here for webcast. Click here to add this event to your calendar. View All Press Releases. 1:00 pm 4:00 pm ET.

investors.diadexus.com investors.diadexus.com

Investors & Media - Diadexus, Inc.

Reverse Split IRS Form 8937. Reverse Split IRS Form 8937. Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA. First cleared by the FDA in 2003 and The PLAC. Cleared in December 2014. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. ...

investors.dicks.com investors.dicks.com

DICK'S Sporting Goods

Skip to main content. Annual Reports and Proxy. Stock Quote and Chart. Dividends, Splits and Repurchases. Annual Reports and Proxy. Stock Quote and Chart. Dividends, Splits and Repurchases. WE ARE THE LARGEST OMNI-CHANNEL FULL-LINE SPORTING GOODS RETAILER IN THE U.S. STORE OPENINGS FOCUS ON NEW AND UNDERPENETRATED MARKETS. FOR EVERY $1 THAT CONSUMERS SPEND ONLINE, THEY WILL SPEND NEARLY $5 IN PHYSICAL STORES." – FORRESTER RESEARCH. DICK’S STORES IN 46 STATES. As of May 2, 2015. Q1 2015 SEC Filing.

investors.diebold.com investors.diebold.com

Diebold | Investor Overview

Sign Up For Email Alerts. There are currently no events scheduled. Q2 2015 Diebold Earnings Conference Call. Thursday, July 30, 2015 8:30 am ET. Click here for webcast. Diebold Direct Stock Purchase Plan. Investor Relations Department 9-B-16. Wells Fargo Shareowner Services. St Paul, MN 55164-0874. 651-450-4064 (if outside the U.S.). Technology Strategy and Innovation Committee. Data provided by Nasdaq. Minimum 15 minutes delayed. CA Supply Chains Act. 2015 Diebold, Incorporated.

investors.diffusionpharma.com investors.diffusionpharma.com

Diffusion Pharmaceuticals Inc. | Investor Overview

Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Overview / Trans Sodium Crocetinate (TSC). Annual Meeting and Proxy Materials. Annual Meeting and Proxy Materials. Diffusion Pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects. December 12, 2016. November 14, 2016. November 08, 2016. Tuesday, June 21, 2016. THE SITE ...

investors.dime.com investors.dime.com

Corporate Profile

News and Market Data. Dime Community Bancshares, Inc. Market Capital ( $. As of January 12, 2017 11:37 AM ET. Kirk Lloyd promoted to Chief Lending Officer Commercial Real Estate. Stuart H. Lubow Joins Dime as Senior Executive Vice President and head of Business Banking. Dime Community Bancshares to Release Earnings on January 26, 2017. Dime Community Bancshares, Inc. Brooklyn, NY 11211. 718) 782-6200 ext. 5260. American Stock Transfer and Trust Co. Brooklyn, NY 11219. S&P Global Market Intelligence.

investors.dineequity.com investors.dineequity.com

DineEquity,Inc. - Investor Relations - Disclaimer

 2015 DineEquity, Inc.Â.

investors.discountbank.co.il investors.discountbank.co.il

Israel Discount Bank - Investor Relations

Israel Discount Bank is a leading financial group in Israel. With nation-wide coverage and a strong domestic franchise, the Bank provides a full spectrum of corporate and retail financial products and services to its clients, both in Israel and in key financial centers around the world. Q2 2015 Conference Call. To join the Bank's presentation click here. 44 (0) 1452 555566. Please provide your name and company's name to the operator. Q2 -15 Financial Results and Conference Call. Q1 2015 Conference Call.

investors.dna.com investors.dna.com

Investors | Overview | Intrexon

Operating Units and Divisions. Agaricus and Neurospora Platforms. Intrexon Institute for Biomolecular Research. Approach to synthetic biology has the potential to provide new, more effective and sustainable solutions to address these challenges. 160; 2.49. Data as of 08/14/15 4:00 pm ET. Minimum 20 minute delay. Intrexon Corporate Presentation August 2015. Intrexon Jefferies Healthcare Presentation June 2015. IRS Form 8937 Related to Special Stock Dividend of ZIOPHARM Shares. Intrexon to Acquire Oxitec, ...

investors.dolphingeo.com investors.dolphingeo.com

Welcome to Dolphin Group | Dolphin Group

Welcome to Dolphin Group. No front page content has been created yet. In cooperation with Alert IR.